John H. Johnson Assumes Role of Chairman
July 3, 2012—-Dendreon Corporation (NASDAQ: DNDN) today announced
that John H. Johnson, president and chief executive officer, has assumed
the additional title of Chairman of the Board, as of July 1, 2012. Mr.
Johnson succeeds Dr. Mitchell H. Gold as Chairman. Dr. Gold will
continue to serve as a director. These changes are part of a succession
plan previously announced on February 1, 2012.
Douglas G. Watson, Lead Independent Director of the Company's Board,
said, "John has proven to be an outstanding leader, and is making
important progress in positioning Dendreon for long-term success. As
Chairman, he will set the vision for Dendreon as we work to provide
PROVENGE® to patients around the world."
Mr. Johnson commented, "This is an exciting time in the prostate cancer
space, and Dendreon has a unique position in the marketplace with an
entirely new treatment paradigm. I look forward to working with the
Board and Dendreon management team as we work to improve our top and
bottom line performance, creating value for shareholders and patients
Dendreon Corporation is a biotechnology company whose mission is to
target cancer and transform lives through the discovery, development,
commercialization and manufacturing of novel therapeutics. The Company
applies its expertise in antigen identification, engineering and cell
processing to produce active cellular immunotherapy (ACI) product
candidates designed to stimulate an immune response in a variety of
tumor types. Dendreon's first product, PROVENGE® (sipuleucel-T), was
approved by the U.S. Food and Drug Administration (FDA) in April 2010.
Dendreon is exploring the application of additional ACI product
candidates and small molecules for the potential treatment of a variety
of cancers. The Company is headquartered in Seattle, Washington, and is
traded on the NASDAQ Global Market under the symbol DNDN. For more
information about the Company and its programs, visit http://www.dendreon.com/.
This news release contains forward-looking statements that are
subject to risks and uncertainties. Factors that could affect these
forward-looking statements include, but are not limited to, developments
affecting Dendreon's business and prospects and potential revenue and
earnings from product sales, and progress generally on commercialization
efforts for PROVENGE. Information on the factors and risks that could
affect Dendreon's business, financial condition and results of
operations are contained in Dendreon's public disclosure filings with
the U.S. Securities and Exchange Commission, which are available at www.sec.gov.
Dendreon cautions investors not to place undue reliance on the
forward-looking statements contained in this press release. All
forward-looking statements are based on information currently available
to Dendreon on the date hereof, and Dendreon undertakes no obligation to
revise or update these forward-looking statements to reflect events or
circumstances after the date of this press release, except as required
April Falcone, 206-829-1622
Source: Dendreon Corporation
News Provided by Acquire Media
Close window | Back to top